Logo

UC Irvine to Validate MicroRNA Dx Tests for Rosetta Genomics

Apr 14, 2008
NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has struck an agreement with the University of California, Irvine, School of Medicine to work together to validate diagnostic tests based on the company’s microRNA technology.
 
Under the agreement, the CLIA-certified medical school and the company will work together to validate tests that are designed to differentiate squamous from non-squamous lung cancer and to differentiate mesothelioma from adenocarcinoma, as well as to identify cancers of unknown primary origin.
 
Rosetta Genomics, which is based in Rehovot, Israel, and has operations in Jersey City, NJ, also said it expects to launch three microRNA diagnostic tests in clinical laboratories sometime this year.
 

Financial terms of the agreement were not released.

Breaking News
The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.